COVID-19 clinical study of baricitinib and remdesivir set-up with the help of AI

• The randomised control trial, which included more than 1,000 patients, began on May 8 to assess the efficacy and safety of baricitinib plus remdesivir versus remdesivir in hospitalised patients with COVID-19
• The results of randomised trials, including the recently initiated global placebo-controlled study, are expected in the next few months
• “This data will allow us to better understand baricitinib’s role in potentially improving outcomes for hospitalised COVID-19 patients, and we look forward to continuing this research alongside our other initiatives to combat COVID-19”

Daniel Skovronsky, M.D., Ph.D., senior VP and chief scientific officer of Eli Lilly

Click here to learn more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: OCT2020HM001